Molecular Templates Company Description
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Craig Jalbert |
Contact Details
Address: 9301 Amberglen Boulevard Austin, Delaware 78729 United States | |
| Phone | 512 869 1555 |
| Website | mtem.com |
Stock Details
| Ticker Symbol | MTEMQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig Jalbert | President, Chief Executive Officer and Chief Financial Officer |